Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | MGLL | Q99685 | 4/20 | 0.69 |
| ▸ | FAAH | O00519 | 2/20 | 0.69 |
| ▸ | GSK3A | P49840 | 2/20 | 0.62 |
| ▸ | GSK3B | P49841 | 2/20 | 0.62 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | THRB | P10828 | 2/20 | 0.54 |
| ▸ | RECQL | P46063 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL146412 | 0.83 | MGLL (1.00) | PTGS1PTGS2MGLLFAAHGSK3A | |
| SCHEMBL1885239 | 0.83 | PTGS1 (0.71) | PTGS1PTGS2MGLLFAAHGSK3A | |
| SCHEMBL14207256 | 0.79 | PTGS1 (0.66) | PTGS1PTGS2ENPP2MEN1KMT2A | |
| SCHEMBL10974744 | 0.79 | GSK3A (0.67) | PTGS1PTGS2MGLLFAAHGSK3A | |
| SCHEMBL24939709 | 0.78 | PTGS1 (0.64) | PTGS1PTGS2ENPP2MEN1KMT2A | |
| SCHEMBL4804503 | 0.78 | MGLL (0.78) | PTGS1PTGS2MGLLFAAHGSK3A | |
| SCHEMBL8950019 | 0.77 | MGLL (0.86) | PTGS1PTGS2MGLLFAAHGSK3A | |
| SCHEMBL21215698 | 0.77 | MGLL (0.86) | PTGS1PTGS2MGLLFAAHGSK3A | |
| SCHEMBL25435490 | 0.77 | MGLL (1.00) | PTGS1PTGS2MGLLFAAHGSK3A | |
| SCHEMBL207740 | 0.77 | MGLL (1.00) | PTGS1PTGS2MGLLFAAHGSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0310413-B1 | Immobilized antibodies | JAPAN CHEM RES (JP) | 1994-03-16 | — | — | EP | claimed |
| EP-0336856-B1 | WITH MALEIMIDE GROUPS FUNCTIONALIZED AROMATIC POLYAMIDEIMIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE FOR PREPARING CROSS-LINKED POLYMERS | CIBA-GEIGY AG (CH) | 1993-03-03 | — | — | EP | claimed |
| US-4927900-A | Aromatic polyamidoimides having maleimido end groups | RHONE-POULENC CHIMIE (FR) | 1990-05-22 | — | — | US | claimed |
| EP-0310413-A2 | Immobilized antibodies | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JCR PHARMACEUTICALS CO., LTD (JP) | 1989-04-05 | — | — | EP | claimed |
| US-20250367317-A1 | COMPOUND HAVING AFFINITY SUBSTANCE TO ANTIBODY AND BIOORTHOGONAL FUNCTIONAL GROUP, OR SALT THEREOF | AJINOMOTO CO., INC. (JP) | 2025-12-04 | — | — | US | disclosed |
| US-20250302985-A1 | COMPOUND HAVING AFFINITY SUBSTANCE TO ANTIBODY AND BIOORTHOGONAL FUNCTIONAL GROUP, OR SALT THEREOF | AJINOMOTO CO., INC. (JP) | 2025-10-02 | — | — | US | disclosed |
| CN-112261954-B | Compounds having affinity substances for antibodies and bio-orthogonalization functional groups or salts thereof | 味之素株式会社 | 2025-06-24 | — | — | CN | disclosed |
| EP-4406975-A2 | COMPOUND HAVING AFFINITY SUBSTANCE TO ANTIBODY AND BIOORTHOGONAL FUNCTIONAL GROUP, OR SALT THEREOF | AJINOMOTO CO., INC. (JP) | 2024-07-31 | — | — | EP | disclosed |
| CN-117801107-A | Benzazepine derivatives, conjugates containing same and application thereof | 上海迪诺医药科技有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-112261954-A | Compound having affinity substance for antibody and bio-orthogonal functional group, or salt thereof | 味之素株式会社 | 2021-01-22 | — | — | CN | disclosed |
| US-9540424-B2 | Serum albumin binding molecules | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540424-B2 | Serum albumin binding molecules | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-10 | — | — | US | disclosed |
| EP-0131361-B1 | COMPLEX OF BIOLOGICALLY ACTIVE PROTEIN WITH REACTIVE HIGH POLYMER HAVING BONDED THERETO BIFUNCTIONAL CHELATE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1989-10-18 | — | — | EP | disclosed |
| EP-0310413-A2 | Immobilized antibodies | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JCR PHARMACEUTICALS CO., LTD (JP) | 1989-04-05 | — | — | EP | disclosed |
| US-4652519-A | Bifunctional chelating agents and process for their production | YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED (IL) | 1987-03-24 | — | — | US | disclosed |
| EP-0177023-A2 | Substance-conjugated complement component C1q | The Calpis Food Industry Co., Ltd. (JP) | 1986-04-09 | — | — | EP | disclosed |
| US-4556689-A | POLYSUCCINIMIDE WITH BONDED AMINE RESIDUE OR DISULFIDE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1985-12-03 | — | — | US | disclosed |
| US-4536391-A | REACTING A PLASMIN HEAVY CHAIN WITH UROKINASE IN THE PRESENCE OF A COUPLING AGENT | OTSUKA PHARMACEUTICAL CO. (JP) | 1985-08-20 | — | — | US | disclosed |
| EP-0131361-A2 | Complex of biologically active protein with reactive high polymer having bonded thereto bifunctional chelate | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1985-01-16 | — | — | EP | disclosed |
| EP-0109653-A2 | Process for preparing urokinase complex | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302985-A1 | COMPOUND HAVING AFFINITY SUBSTANCE TO ANTIBODY AND BIOORTHOGONAL FUNCTIONAL GROUP, OR SALT THEREOF | FCGR3B, SIGLEC7, SIGLEC9 | PTGS1 3257/4885PTGS2 3447/4885MGLL 379/4885 |
| US-20250367317-A1 | COMPOUND HAVING AFFINITY SUBSTANCE TO ANTIBODY AND BIOORTHOGONAL FUNCTIONAL GROUP, OR SALT THEREOF | FCGR3B, SIGLEC7, SIGLEC9 | PTGS1 3257/4885PTGS2 3447/4885MGLL 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.